secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001437749-23-031249
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q3 net loss $37.8M; discontinues IgA nephropathy trial, targets narsoplimab BLA in mid-2024
--------------------------------------------------------------------------------

- Net loss of $37.8M ($0.60/sh) vs $17.5M prior year; continuing ops loss $51.7M, down from $54.8M.
- OMIDRIA royalties $10.0M on $33.3M US sales (down from $16.5M) due to royalty rate drop to 30%.
- $310.3M cash as of Sept 30; expects to repay $95M convertible notes due Nov 15, 2023.
- Phase 3 ARTEMIS-IGAN trial for IgA nephropathy discontinued after interim analysis missed primary endpoint.
- BLA resubmission for narsoplimab in TA-TMA on track for FDA decision mid-2024; OMS906 Phase 2 PNH data pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774923031249/0001437749-23-031249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774923031249/omer20230905_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-031249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer